Prophylactic automatic implantable cardioverter-defibrillator patches in patients at high risk for postoperative ventricular tachyarrhythmias.

J Am Coll Cardiol

Department of Medicine, Tufts University School of Medicine, New England Medical Center, Boston, Massachusetts 02111.

Published: May 1989

The strategy of placing prophylactic patches for the automatic implantable cardioverter-defibrillator (AICD) without the AICD was employed in 34 patients with coronary artery disease at risk for postoperative ventricular tachycardia undergoing coronary bypass graft surgery (12 patients) or subendocardial resection (22 patients). Patients were selected on the basis of the presence of preoperative sustained ventricular tachycardia (25 patients) or ventricular fibrillation (9 patients) and absence of control of the arrhythmia with 3.6 +/- 1.3 antiarrhythmic drugs by programmed stimulation. Patients having subendocardial resection were also selected on the basis of multiple configurations of ventricular tachycardia, inability to map the tachycardia or posterior wall aneurysm. The surgical mortality rate was 12%, with two deaths after coronary bypass graft surgery and two deaths after subendocardial resection. The AICD patches were removed in 1 of the 34 patients a few hours after surgery because of left atrial laceration and bleeding. Among 10 patients surviving coronary bypass surgery alone, ventricular arrhythmia was not inducible in 6 and in 4 it remained inducible postoperatively. One of the four patients with inducible arrhythmia had the AICD implanted with use of local anesthesia; the other three were treated with drugs. Among 20 patients surviving subendocardial resection, ventricular arrhythmia was noninducible in 15 and remained inducible in 5. Three of these five patients had an AICD implanted; the other two were treated with drugs. At 12 +/- 7 month follow-up, there were no late deaths.(ABSTRACT TRUNCATED AT 250 WORDS)

Download full-text PDF

Source
http://dx.doi.org/10.1016/0735-1097(89)90312-4DOI Listing

Publication Analysis

Top Keywords

subendocardial resection
16
patients
13
ventricular tachycardia
12
coronary bypass
12
automatic implantable
8
implantable cardioverter-defibrillator
8
risk postoperative
8
postoperative ventricular
8
bypass graft
8
graft surgery
8

Similar Publications

Article Synopsis
  • Primary cardiac tumors (PCTs) like myxomas and lipomas are rare, with lipomas being soft fat masses that can lead to diagnostic challenges.
  • Lipomatous hypertrophy of the atrial septum (LHAS) is a benign condition linked to aging and obesity, distinct from true cardiac lipomas.
  • A case of a true atrial septal lipoma discovered during heart dissection is detailed, highlighting its potential effects on heart function and contributing to the scarce literature on benign primary cardiac tumors.
View Article and Find Full Text PDF

Objectives: To evaluate the safety and efficacy of the port access approach for left atrial (LA) myxoma resection and to analyze the learning curve for this procedure.

Methods: Thirty-six consecutive patients with LA myxoma who underwent port access surgery between April 2018 and March 2023 were enrolled in this retrospective study. The procedure included (1) unilateral or bilateral femoral artery cannulation; (2) the use of three 5-mm trocars and a 20- to 30-mm port; (3) a transseptal, biatrial, or LA approach depending on the location of the tumor base; and (4) complete or subendocardial tumor resection.

View Article and Find Full Text PDF

Endocardial fibroelastosis (EFE), defined by subendocardial tissue accumulation, has major impacts on the development of the left ventricle (LV) and precludes patients with congenital critical aortic stenosis and hypoplastic left heart syndrome (HLHS) from curative anatomical biventricular surgical repair. Surgical resection is currently the only available therapeutic option, but EFE often recurs, sometimes with an even more infiltrative growth pattern into the adjacent myocardium. To better understand the underlying mechanisms of EFE and to explore therapeutic strategies, an animal model suitable for preclinical testing was developed.

View Article and Find Full Text PDF

Endomyocardiofibrosis (EMF) is a restrictive cardiomyopathy characterized by subendocardial fibrosis due to eosinophilic myocardial infiltration. EMF may commonly present with heart failure (HF) or atrial fibrillation (AF). Immunosuppression can be effective in early stages, but not in the chronic phase.

View Article and Find Full Text PDF

There is more than 58-year experience of surgical treatment of patients with intracardiac myxomas at the Petrovsky National Research Center of Surgery. Primary delayed growth of the right and left atrial myxoma after 21 years and 5 months was observed only in 1 (0.36%) patient.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!